A Study of Pembrolizumab With or Without Lenvatinib as First Line Intervention in a Programmed Cell Death-ligand 1 Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck